Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Jacqueline Garcia, MD
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07439211CT.gov Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia | — | Not Yet Recruiting | — | — | — |
NCT06429449CT.gov Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia | — | Recruiting | — | — | — |
NCT04748848CT.gov A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy | — | Terminated | — | — | — |
NCT03066648CT.gov Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS | — | Completed | — | — | — |
NCT02577406CT.gov An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation | — | Completed | — | — | — |
NCT02203773CT.gov Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myeloid Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Azacitidine (this asset) | Jacqueline Garcia, MD | P3 | B · 61 |
| Fludarabine | M.D. Anderson Cancer Center | P2/3 | BBB |
| Cyclophosphamide | Actinium Pharmaceuticals | P2/3 | BB |
| Nivestim | M.D. Anderson Cancer Center | P2 | BB |
| Cytarabine | M.D. Anderson Cancer Center | P3 | BB |
| Sirolimus | Masonic Cancer Center, University of Minnesota | P2 | BB |
| Tacrolimus | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | P2 | BB |
| Melphalan | Dana-Farber Cancer Institute | P2 | B |
| Enasidenib | Tian Yi Zhang | P3 | B |
+42 more in the Myeloid Leukemia cohort
Other indications for Azacitidine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 73 |
| Acute Erythroid Leukemia | — | P2 | BB · 71 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Azacitidine in Myeloid Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/azacitidine-myeloid-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →